Harbour Investments Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Harbour Investments Inc. increased its Gilead Sciences stake by 172.8% in the fourth quarter, ending with 19,521 shares valued at about $2.4 million.
• Gilead reported better-than-expected quarterly results, posting EPS of $2.03 versus $1.91 expected and revenue of $6.96 billion, up 4.4% year over year.
• The company also announced a quarterly dividend of $0.82 per share, equal to an annualized payout of $3.28 and a yield of about 2.5%.

Harbour Investments Inc. raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 172.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,521 shares of the biopharmaceutical company's stock after acquiring an additional 12,365 shares during the quarter. Harbour Investments Inc.'s holdings in Gilead Sciences were worth $2,396,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in GILD. Ares Financial Consulting LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $28,000. Financial Consulate Inc. grew its holdings in shares of Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 109 shares in the last quarter. North Star Investment Management Corp. grew its holdings in shares of Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 86 shares in the last quarter. MTM Investment Management LLC grew its holdings in shares of Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 176 shares in the last quarter. Finally, BOCHK Asset Management Ltd purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $31,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares of the company's stock, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business's stock in a transaction on Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the transaction, the chief financial officer directly owned 173,191 shares in the company, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 63,000 shares of company stock valued at $8,523,570. Corporate insiders own 0.30% of the company's stock.

Gilead Sciences Trading Down 0.0%

Shares of GILD stock opened at $133.69 on Thursday. The stock has a market cap of $165.99 billion, a price-to-earnings ratio of 18.21 and a beta of 0.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a fifty-two week low of $104.46 and a fifty-two week high of $157.29. The firm's 50 day moving average price is $135.60 and its two-hundred day moving average price is $133.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to analysts' expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences's revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences's payout ratio is 44.69%.

Analysts Set New Price Targets

A number of brokerages have recently commented on GILD. Mizuho lifted their price target on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock an "outperform" rating in a report on Wednesday, February 18th. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an "overweight" rating in a report on Wednesday, February 11th. Wall Street Zen downgraded shares of Gilead Sciences from a "strong-buy" rating to a "hold" rating in a report on Saturday, May 9th. Cantor Fitzgerald lowered their price target on shares of Gilead Sciences from $155.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, April 10th. Finally, Royal Bank Of Canada lowered their price target on shares of Gilead Sciences from $123.00 to $122.00 and set a "sector perform" rating for the company in a report on Friday, May 8th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $156.93.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.